Schedule 13G ownership disclosure
Enanta Pharmaceuticals Inc
Common Stock, par value $0.01 per share (the "Shares") · CUSIP: 29251M106
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Farallon Capital Partners, L.P.
Shares: 531,119 · Class: 1.8%
- Farallon Capital Institutional Partners, L.P.
Shares: 595,851 · Class: 2.1%
- Farallon Capital Institutional Partners II, L.P.
Shares: 150,355 · Class: 0.5%
- Farallon Capital Institutional Partners III, L.P.
Shares: 84,528 · Class: 0.3%
- Four Crossings Institutional Partners V, L.P.
Shares: 108,002 · Class: 0.4%
- Farallon Capital Offshore Investors II, L.P.
Shares: 1,110,733 · Class: 3.8%
- Farallon Capital (AM) Investors, L.P.
Shares: 60,191 · Class: 0.2%
- Farallon Capital F5 Master I, L.P.
Shares: 176,083 · Class: 0.6%
- Farallon Partners, L.L.C.
Shares: 2,640,779 · Class: 9.1%
- Farallon Institutional (GP) V, L.L.C.
Shares: 108,002 · Class: 0.4%
- Farallon F5 (GP), L.L.C.
Shares: 176,083 · Class: 0.6%
- Dapice Joshua J.
Shares: 2,816,862 · Class: 9.8%
- Dreyfuss, Philip D.
Shares: 2,816,862 · Class: 9.8%
- Dunn Hannah E.
Shares: 2,816,862 · Class: 9.8%
- Fried, Richard B
Shares: 0 · Class: 0%
- Gehani, Varun N.
Shares: 2,816,862 · Class: 9.8%
- Giauque, Nicolas
Shares: 2,816,862 · Class: 9.8%
- Husen, Avner A.
Shares: 2,816,862 · Class: 9.8%
- Kim, David T.
Shares: 2,816,862 · Class: 9.8%
- Linn, Michael G.
Shares: 2,816,862 · Class: 9.8%
- Luo Patrick (Cheng)
Shares: 2,816,862 · Class: 9.8%
- Patel, Rajiv A.
Shares: 0 · Class: 0%
- Roberts, Jr., Thomas G.
Shares: 2,816,862 · Class: 9.8%
- Saito Edric C.
Shares: 2,816,862 · Class: 9.8%
- Seybold, William
Shares: 0 · Class: 0%
- Short Daniel S.
Shares: 2,816,862 · Class: 9.8%
- Spokes, Andrew J. M.
Shares: 2,816,862 · Class: 9.8%
- Warren, John R.
Shares: 2,816,862 · Class: 9.8%
- Wehrly, Mark C.
Shares: 2,816,862 · Class: 9.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000908834-26-000042
- Form type
- SCHEDULE 13G/A
- Filer
- ENANTA PHARMACEUTICALS INC
- CIK
- CIK 1177648
- Filed
- Feb 05, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership